Alteration in immune function in patients with fatty liver disease

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a disease spectrum that spans simple steatosis, fibrosis, and ultimately cirrhosis, and is a leading cause of chronic liver disease globally. The severe variant of NAFLD, non-alcoholic steatohepatitis (NASH), is characterized by triglyceride accumulation within hepatocytes and the subsequent inflammatory pathway activation, ultimately progressing to cirrhosis in 10%-20% of patients. NASH is a known major risk factor for the development of hepatocellular carcinoma (HCC), and there is emerging data demonstrating the impact of NASH on immune subsets and the tumor microenvironment that may influence therapeutic response. This review describes the various ways in which the immune system is altered in patients with NASH. The innate immune system in NASH shows alterations in dendritic and Kupffer cells, impaired cytotoxicity of Natural Killer cells, and an accumulation of neutrophils. Additionally, there is emerging evidence emphasizing the role of the adaptive immune system in the development and progression of NASH, seen in the alteration of B-cells, T-cells, and NKT Cells. Due to the complex interplay of the immune system in NAFLD/NASH and its progression to HCC, many current treatments focus on targeting immune cells for HCC therapy. Recently, immune checkpoint inhibitors such as atezolizumab and bevacizumab have been approved as first-line therapy for unresectable HCC. Although an emerging field of research, further studies and clinical trials are needed to understand the complex interface of NASH, HCC and the immune response.

Keywords

Non-alcoholic steatohepatitis / nonalcoholic fatty liver disease / steatohepatitis / immunology / hepatocellular carcinoma

References

[1] Loomba R.The global NAFLD epidemic.Nat Rev Gastroenterol Hepatol2013;10:686-90

[2] Chalasani N,Lavine JE.The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.Hepatology2018;67:328-57

[3] Anstee QM,Kotsiliti E,Heikenwalder M.From NASH to HCC: current concepts and future challenges.Nat Rev Gastroenterol Hepatol2019;16:411-28

[4] Machado MV.Pathogenesis of nonalcoholic steatohepatitis.Gastroenterology2016;150:1769-77

[5] Michelotti GA,Diehl AM.NAFLD, NASH and liver cancer.Nat Rev Gastroenterol Hepatol2013;10:656-65

[6] Sheka AC,Ikramuddin S.Nonalcoholic steatohepatitis-reply.JAMA2020;324:899-900

[7] Huang DQ,Loomba R.Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol2021;18:223-38 PMCID:PMC8016738

[8] Estes C,Arias-Loste MT.Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.J Hepatol2018;69:896-904

[9] White DL,El-Serag HB.Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.Clin Gastroenterol Hepatol2012;10:1342-1359.e2 PMCID:PMC3501546

[10] Forner A,Bruix J.Hepatocellular carcinoma.Lancet2018;391:1301-14

[11] Llovet JM,Pikarsky E.Hepatocellular carcinoma.Nat Rev Dis Primers2016;2:16018

[12] Maluccio MA,Porat LB.Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma.J Vasc Interv Radiol2008;19:862-9

[13] Llovet JM,Montaña X.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.Lancet2002;359:1734-9

[14] Maluccio M,Gandhi R.Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm.J Vasc Interv Radiol2005;16:955-61

[15] Raoul JL,Bolondi L,Kloeckner R.Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence.Cancer Treat Rev2019;72:28-36

[16] Finn RS,Merle P.KEYNOTE-240 investigatorsPembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial.J Clin Oncol2020;38:193-202

[17] Greten TF,Cheng AL.Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.J Immunother Cancer2021;9:e002794 PMCID:PMC8438858

[18] Cusi K.Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.Gastroenterology2012;142:711-725.e6

[19] Dixon JB,Hughes NR.Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss.Hepatology2004;39:1647-54

[20] Yang JD,Mara KC.Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease.Hepatology2020;71:907-16 PMCID:PMC6960360

[21] Rotman Y,Zmuda JM,Liang TJ.NASH CRNThe association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease.Hepatology2010;52:894-903

[22] Prieto J,Sangro B.Immunological landscape and immunotherapy of hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol2015;12:681-700

[23] Jenne CN.Immune surveillance by the liver.Nature immunology2013;14:996

[24] Brown ZJ,Heinrich B.Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy.Hepatology2019;70:1437-42

[25] Koo SY,Lee CW.Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma.Exp Mol Med2020;52:1209-19 PMCID:PMC8080649

[26] Agosti P,Mazzocca A.Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment.Biochim Biophys Acta Mol Basis Dis2018;1864:607-17

[27] Stauffer JK,Jiang Q.Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections.Hepatology2012;56:1567-74 PMCID:PMC3381981

[28] Fattovich G,Zagni I.Hepatocellular carcinoma in cirrhosis: incidence and risk factors.Gastroenterology2004;127:S35-50

[29] Hernandez-Gea V,Friedman SL.Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.Gastroenterology2013;144:512-27 PMCID:PMC3578068

[30] Arrese M,Kalergis AM.Innate immunity and inflammation in NAFLD/NASH.Dig Dis Sci2016;61:1294-303 PMCID:PMC4948286

[31] Racanelli V.The liver as an immunological organ.Hepatology2006;43:S54-62

[32] Tacke F.Targeting hepatic macrophages to treat liver diseases.J Hepatol2017;66:1300-12

[33] Nakamoto N.Role of toll-like receptors in immune activation and tolerance in the liver.Front Immunol2014;5:221 PMCID:PMC4032908

[34] Soares JB,Roncon-Albuquerque R.The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases.Hepatol Int2010;4:659-72 PMCID:PMC2994611

[35] Kim SY,Kim SJ.Pro-inflammatory hepatic macrophages generate ROS through NADPH oxidase 2 via endocytosis of monomeric TLR4-MD2 complex.Nat Commun2017;8:2247 PMCID:PMC5740170

[36] Seki E.Hepatic inflammation and fibrosis: functional links and key pathways.Hepatology2015;61:1066-79 PMCID:PMC4306641

[37] Feldstein AE,Angulo P.Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis.Gastroenterology2003;125:437-43

[38] Mridha AR,Yeh MM.TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.Clin Sci2017;131:2145-59

[39] Garcia-Martinez I,Chen Y.Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9.J Clin Invest2016;126:859-64 PMCID:PMC4767345

[40] Sarkar S,Seth RK.Higher intestinal and circulatory lactate associated NOX2 activation leads to an ectopic fibrotic pathology following microcystin co-exposure in murine fatty liver disease.Comp Biochem Physiol C Toxicol Pharmacol2020;238:108854 PMCID:PMC7541568

[41] Gabbia D,De Martin S.The Role of Oxidative Stress in NAFLD-NASH-HCC Transition-Focus on NADPH Oxidases.Biomedicines2021;9:687 PMCID:PMC8235710

[42] Polimeni L,Baratta F.Oxidative stress: new insights on the association of non-alcoholic fatty liver disease and atherosclerosis.World J Hepatol2015;7:1325-36 PMCID:PMC4450196

[43] Holt MP,Ju C.Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury.J Leukoc Biol2008;84:1410-21 PMCID:PMC2614594

[44] Stienstra R,Duval C.Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity.Hepatology2010;51:511-22

[45] Obstfeld AE,Thearle M.C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis.Diabetes2010;59:916-25 PMCID:PMC2844839

[46] Baeck C,Karlmark KR.Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.Gut2012;61:416-26

[47] Lefebvre E,Reshef R.Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis.PLoS One2016;11:e0158156 PMCID:PMC4922569

[48] Kahraman A,Kocabayoglu P.Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis.Hepatology2010;51:92-102

[49] Abul K.Abbas AHL, Shiv Pillai. Cellular and molecular immunology.Saunders Elsevier2007;566

[50] Male V,Easom NJ.Natural killer cells in liver disease.Semin Liver Dis2017;37:198-209

[51] Martínez-Chantar ML,Beraza N.Revisiting the role of natural killer cells in non-alcoholic fatty liver disease.Front Immunol2021;12:640869 PMCID:PMC7930075

[52] Amer J,Noureddin M.Insulin signaling as a potential natural killer cell checkpoint in fatty liver disease.Hepatol Commun2018;2:285-98 PMCID:PMC5831020

[53] Radaeva S,Jaruga B,Tian Z.Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners.Gastroenterology2006;130:435-52

[54] Cai L,Zhou L.Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients.Clin Immunol2008;129:428-37

[55] Feng M,Anver M,Ho M.In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice.J Cancer2011;2:123-31 PMCID:PMC3072618

[56] Lalor PF,Aarbodem Y,Adams DH.The role of cytokines and chemokines in the development of steatohepatitis.Semin Liver Dis2007;27:173-93

[57] Rensen SS,Nijhuis J.Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis.Am J Pathol2009;175:1473-82 PMCID:PMC2751544

[58] van der Windt DJ,Zhang H.Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis.Hepatology2018;68:1347-60 PMCID:PMC6173613

[59] Wang H,Wang Y.Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis.J Hepatol2021;75:1271-83

[60] Henning JR,Rehman A.Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice.Hepatology2013;58:589-602 PMCID:PMC3638069

[61] Huby T.Immune cell-mediated features of non-alcoholic steatohepatitis.Nat Rev Immunol2022;22:429-43 PMCID:PMC8570243

[62] Silva NS, Klein U. Dynamics of B cells in germinal centres.Nat Rev Immunol2015;15:137-48 PMCID:PMC4399774

[63] Fillatreau S.B cells and their cytokine activities implications in human diseases.Clin Immunol2018;186:26-31 PMCID:PMC5844600

[64] Bruzzì S,Giudici G.B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD).Free Radic Biol Med2018;124:249-59

[65] Garnelo M,Her Z.Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma.Gut2017;66:342-51 PMCID:PMC5284473

[66] Sutti S.Adaptive immunity: an emerging player in the progression of NAFLD.Nat Rev Gastroenterol Hepatol2020;17:81-92 PMCID:PMC7222953

[67] Shalapour S,Bastian IN.Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity.Nature2017;551:340-5

[68] Ramadori P,Heikenwalder M.T cells: friends and foes in NASH pathogenesis and hepatocarcinogenesis.Hepatology2022;75:1038-49

[69] Heinrich B,Diggs LP.Steatohepatitis impairs T-cell-directed immunotherapies against liver tumors in mice.Gastroenterology2021;160:331-345.e6 PMCID:PMC7755834

[70] Kang TW,Woller N.Senescence surveillance of pre-malignant hepatocytes limits liver cancer development.Nature2011;479:547-51

[71] Rakhra K,Zabuawala T.CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.Cancer Cell2010;18:485-98 PMCID:PMC2991103

[72] Ma C,Eggert T.NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.Nature2016;531:253-7 PMCID:PMC4786464

[73] Brown ZJ,Ma C.Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4⁺ T cell apoptosis promoting HCC development.Cell Death Dis2018;9:620 PMCID:PMC5966464

[74] Sutti S,Locatelli I.Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH.Hepatology2014;59:886-97

[75] Van Herck MA,Kwanten WJ.The differential roles of T cells in non-alcoholic fatty liver disease and obesity.Front Immunol2019;10:82 PMCID:PMC6372559

[76] Hirsova P,Wang H,Revelo XS.Emerging roles of T cells in the pathogenesis of nonalcoholic steatohepatitis and hepatocellular carcinoma.Front Endocrinol (Lausanne)2021;12:760860 PMCID:PMC8581300

[77] MacParland SA,Ma XZ.Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations.Nat Commun2018;9:4383 PMCID:PMC6197289

[78] Crispe IN.Hepatic T cells and liver tolerance.Nat Rev Immunol2003;3:51-62

[79] Ghazarian M,Nøhr MK.Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome.Sci Immunol2017;2:eaai7616 PMCID:PMC5447456

[80] Togashi Y,Nishikawa H.Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.Nat Rev Clin Oncol2019;16:356-71

[81] Geissmann F,Sidobre S.Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids.PLoS Biol2005;3:e113 PMCID:PMC1073691

[82] Kumar V.NKT-cell subsets: promoters and protectors in inflammatory liver disease.J Hepatol2013;59:618-20 PMCID:PMC4086465

[83] Syn WK,Pereira TA.Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease.Hepatology2010;51:1998-2007 PMCID:PMC2920131

[84] Syn WK,Swiderska M.NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease.Gut2012;61:1323-9 PMCID:PMC3578424

[85] Syn WK,Liaskou E.Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis.Hepatology2011;53:106-15 PMCID:PMC3025083

[86] Diao H,Iwabuchi K.Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases.Immunity2004;21:539-50

[87] Wolf MJ,Piotrowitz K.Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes.Cancer Cell2014;26:549-64

[88] Friedman SL,Rinella M.Mechanisms of NAFLD development and therapeutic strategies.Nat Med2018;24:908-22 PMCID:PMC6553468

[89] Llovet JM,Mazzaferro V.SHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinoma.N Engl J Med2008;359:378-90

[90] Greten TF,Li G.Targeted and immune-based therapies for hepatocellular carcinoma.Gastroenterology2019;156:510-24 PMCID:PMC6340758

[91] Kudo M,Qin S.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.The Lancet2018;391:1163-1173

[92] Brown ZJ,Hewitt DB.Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.Surg Oncol2022;42:101748

[93] Borghaei H,Horn L.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.N Engl J Med2015;373:1627-39 PMCID:PMC5705936

[94] Robert C,Brady B.Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med2015;372:320-30

[95] Finn RS,Ikeda M.IMbrave150 InvestigatorsAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905

[96] Lee MS,Hsu C.Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.The Lancet Oncology2020;21:808-20

[97] Ducreux M,Cheng A.IMbrave150: exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).JCO2021;39:4071-4071

[98] Kim BK,Kim H.Atezolizumab/Bevacizumab vs. Lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center study.Cancers2022;14:1747 PMCID:PMC8996911

[99] Pfister D,Pinyol R.NASH limits anti-tumour surveillance in immunotherapy-treated HCC.Nature2021;592:450-6 PMCID:PMC8046670

[100] Kelley RK.Hepatocellular carcinoma - origins and outcomes.N Engl J Med2021;385:280-2